‘Biotech fantasy’? This startup wants to kill cancer by targeting RNA with new generation of pills

| | April 29, 2019
e b h f pill copy
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

Arrakis Therapeutics is named for the desert planet in the legendary “Dune” series of science-fiction novels. It’s an apt name because the Waltham, Mass., startup is trying to achieve a feat once thought to be biotech fantasy: Develop oral medicines — pills — that can target RNA, the messenger-like molecules that turn genetic instructions into proteins.

On [April 24], the company is announcing an early breakthrough. Arrakis’ screening work has identified “hits” — oral drug-like compounds — that block the RNA machinery needed to make some well-known, cancer-causing proteins long thought to be beyond the reach of drug makers.

Some of the compounds found by Arrakis work against myc, one of the first so-called oncogenes identified in the very early 1980s. Myc is believed to play a role in about 70% of all human tumors, but no one has yet figured out a way to develop a drug against it.

Related article:  Inside the quest to find a place in modern medicine for magic mushrooms as a treatment for depression, other mental illnesses

To be crystal clear, Arrakis hasn’t fully solved the myc puzzle either, but it’s no longer a crazy pipe dream, said Michael Gilman, Arrakis’ CEO.

“I think we’ve achieved escape velocity,” he said, leaning on a rocket ship analogy that befits a biotech with a sci-fi inspired name.

Read full, original post: A biotech startup’s lofty goal: Kill cancer with pills that target RNA instead of proteins

Outbreak
Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
a a b b a f ac a

Video: Death by COVID: The projected grim toll in historical context

The latest statistics, as of July 10, show COVID-19-related deaths in U.S. are just under 1,000 per day nationally, which is ...
mag insects image superjumbo v

Disaster interrupted: Which farming system better preserves insect populations: Organic or conventional?

A three-year run of fragmentary Armageddon-like studies had primed the journalism pumps and settled the media framing about the future ...
dead bee desolate city

Are we facing an ‘Insect Apocalypse’ caused by ‘intensive, industrial’ farming and agricultural chemicals? The media say yes; Science says ‘no’

The media call it the “Insect Apocalypse”. In the past three years, the phrase has become an accepted truth of ...
types of oak trees

Infographic: Power of evolution? How oak trees came to dominate North American forests

Over the course of some 56 million years, oaks, which all belong to the genus Quercus, evolved from a single undifferentiated ...
biotechnology worker x

Can GMOs rescue threatened plants and crops?

Some scientists and ecologists argue that humans are in the midst of an "extinction crisis" — the sixth wave of ...
food globe x

Are GMOs necessary to feed the world?

Experts estimate that agricultural production needs to roughly double in the coming decades. How can that be achieved? ...
eating gmo corn on the cob x

Are GMOs safe?

In 2015, 15 scientists and activists issued a statement, "No Scientific consensus on GMO safety," in the journal Environmental Sciences ...
Screen Shot at PM

Charles Benbrook: Agricultural economist and consultant for the organic industry and anti-biotechnology advocacy groups

Independent scientists rip Benbrook's co-authored commentary in New England Journal calling for reassessment of dangers of all GMO crops and herbicides ...
Screen Shot at PM

ETC Group: ‘Extreme’ biotechnology critic campaigns against synthetic biology and other forms of ‘extreme genetic engineering’

The ETC Group is an international environmental non-governmental organization (NGO) based in Canada whose stated purpose is to monitor "the impact of emerging technologies and ...
Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend